Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 55Recurrence 6Neoplasms, Plasma Cell 3Plasmacytoma 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Various Advanced Cancer 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Personal Satisfaction 1Patient Satisfaction 1Patient Preference 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Carcinoma, Renal Cell 1Amyloidosis 1Acute Kidney Injury 1

Interventions

daratumumab 1Stents 1Renal Replacement Therapy 1Plasma Exchange 1Nephrotomy 1Nephrostomy, Percutaneous 1Hyperthermic Intraperitoneal Chemotherapy 1Antibiotic Prophylaxis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Acute Kidney Injury × daratumumab × Clear all
NCT06549634 2026-02-27

Biomarkers of AKI in Patients Receiving Daratumumab

Brigham and Women's Hospital

Completed
20 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡